TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02047552

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: Iron sucrose 100 mg IV will be dosed daily for up to seven days if, on morning laboratory analysis, (1) TSAT \< 25%, (2) Serum iron concentration \< 150 ug/mL, and (3) Serum ferritin concentration \< 1,500 ng/mL. Thus, the maximum possible cumulative dose of iron sucrose over the one-week dosing period will be 700 mg.
Study: NCT02643979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketofol
Description: 50mg of Ketamine mixed with 100mg of Propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 100mg of Propofol
Study: NCT02047552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron sucrose
Description: Iron sucrose 100 mg IV will be dosed daily for up to seven days if, on morning laboratory analysis, (1) TSAT \< 25%, (2) Serum iron concentration \< 150 ug/mL, and (3) Serum ferritin concentration \< 1,500 ng/mL. Thus, the maximum possible cumulative dose of iron sucrose over the one-week dosing period will be 700 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxandrolone
Description: 10 mg PO Q12 hours for seven days
Study: NCT00899847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine is administered by mouth (PO) for allo-PBSC graft vs host disease (GvHD) prophylaxis at 5 mg/kg from Day -3 through Bay +56. Tacrolimus may substituted.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation
Description: Total lymphoid irradiation is administered at 80 centigrey (cGy) on Day -11 to -7; and Day -4 to -2 before alllo-PBSC infusion. TLI is also administered at 80 centigrey (cGy) x 2 on Day -1 before alllo-PBSC infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabbit anti-thymocyte globulin
Description: ATG 1.5 mg/kg is administered intravenously (IV) on Day -11 to -7 before allo-PBSC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil 250mg
Description: MMF is administered at 15 mg/kg 3x/day by mouth (PO) after allo-PBSC through Day 40, followed by 10% dose reduction weekly (dose taper) through day 96, and adjusted if there is evidence of MMF-related GI toxicity or excessive myelosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solumedrol
Description: Solumedrol 1 mg/kg is administered intravenously (IV) on Day -11 to -7 as a premedication for ATG and allo-PBSC infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine 25 to 50 mg is administered as a premedication for the ATG; allo-PBSC; and DLI infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 650 mg is administered as a premedication for the ATG and allo-PBSC infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone 100 mg is administered intravenously (IV) is a premedication for the allo-PBSC and DLI infusions.
Study: NCT00385229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction of labor
Description: Misoprostol, Dinoprostone, amniotomy, Oxytocin
Study: NCT02047552

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxandrolone
Description: 10 mg PO Q12 hours for seven days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV iron placebo
Description: 100 mL normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV iron placebo
Description: 100 mL normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxandrolone placebo
Description: similar color and size sugar pill

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxandrolone placebo
Description: similar color and size sugar pill
Study: NCT05937711

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Posterior Tibial Nerve Stimulation + Duloxetine 30 MG
Description: PTNS was applied using two 50 mm × 50 mm electrode pads per extremity. The live pad was placed superior to and medial to the medial malleolus. The ground pad was placed 5-10 cm proximal to the live pad. The PTNS was applied using biphasic square waves with a frequency of 10 Hz and pulse duration of 200 μs. The amplitude was adjusted to the level that produced painless paresthesia in each patient according to their tolerance. PTNS was applied for 30 minutes~Duloxetine 30 mg p.o 1X1 (daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine 30 MG
Description: Duloxetine 30 mg p.o 1X1 (daily)
Study: NCT01267955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT05937711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 30 MG
Description: Duloxetine 30 mg p.o 1X1 (daily)
Study: NCT00588679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging; Spectroscopic Imaging, Contrast Enhanced Imaging
Description: All MR examinations will be performed on a 3.0 Tesla whole body GE MR scanner located at the main campus (1275 York Avenue) or the Breast and Imaging Center (BAIC)(located on Second Ave. between 65th and 66th Streets). The MR examination will include MR imaging and spectroscopic imaging employing a combined torso phased array and endorectal coil receiver. The examination will require one hour to one hour and ten minutes.
Study: NCT02259231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules (2.5 mg/capsule)
Description: Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules (2.5 mg/capsule)
Description: Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab (3 mg/kg)
Description: Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab (3 mg/kg)
Description: Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg)
Description: Sterile solution containing nivolumab to be delivered intravenously at 240 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg)
Description: Sterile solution containing nivolumab to be delivered intravenously at 240 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg)
Description: Sterile solution containing nivolumab to be delivered intravenously at 240 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg)
Description: Sterile solution containing nivolumab to be delivered intravenously at 240 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg)
Description: Sterile solution containing nivolumab to be delivered intravenously at 240 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules (10 mg/capsule)
Description: Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules (10 mg/capsule)
Description: Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules (10 mg/capsule)
Description: Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules (50 mg/capsule)
Description: Capsules containing 50 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules (50 mg/capsule)
Description: Capsules containing 50 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
Study: NCT01515072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RIPC (Remote Ischemic Preconditioning)
Description: Remote Ischemic Preconditioning (RIPC) by Inflation of Pneumatic Tourniquet. The intervention will consist of tourniquet inflation on the mid-thigh for 5 minutes, followed by a deflation period of 5 minutes for a total of 4 cycles. The intervention will take place at two time points: First, after determination of brain death and consent for organ donation and again upon incision for organ recovery. The second intervention will occur in a manner identical to the first intervention but in the opposite limb.
Study: NCT03135093

Intervention type: OTHER
Intervention: No intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No intervention
Description: No Intervention
Study: NCT01508676

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pennsaid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (2.3% DMSO solution)
Study: NCT03303430

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Diffusion weighted imaging 24 hours after revascularisation

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Diffusion weighted imaging 24 hours after revascularisation
Study: NCT00567931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1-methyl-d-tryptophan
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03652454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: micro-osteoperforation
Description: Propel device (ABD) using for regional acceleratory phenomenon

Intervention type: OTHER
Group type: OTHER
Intervention: conventional fixed appliance treatment
Description: conventional fixed appliance treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional fixed appliance treatment
Description: conventional fixed appliance treatment
Study: NCT00929630

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transsphincteric Seton positioning
Description: A cutting seton is applied into the fistula tract

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: glue (Tissucol) treatment
Description: After preparation of the fistula, a quantity of biological glue (Tissucol) is injected into the fistula tract

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fistula closing with biological glue
Description: After cleaning and disinfection of the fistula tract, abot 1-2 ml of Tissucol (biological Glue) is inserted into the fistula tract to close it

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Seton positioning into the fistula tract
Description: Under spinal anesthesia a Seton is positioned into the fistula tract.
Study: NCT02228499

Intervention type: OTHER
Intervention: Survey
Description: We will be administering surveys about health, quality of life, and asking for final report cards for the 2013-2014 school year for each group.

Intervention type: OTHER
Intervention: Survey
Description: We will be administering surveys about health, quality of life, and asking for final report cards for the 2013-2014 school year for each group.
Study: NCT01677845

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Dose Level 1: 54 Gy; 3 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions;~Dose Level 2: 55.8 Gy; 3.1 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions;~Dose Level 3: 57.6 Gy; 3.2 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions.
Study: NCT04476264

Intervention type: PROCEDURE
Intervention: Novel use of an adjustable single 8-0 polypropylene suture of scleral fixation without conjunctival dissection
Description: The present study serves to describe a novel approach to utilizing a single adjustable 8-0 polypropylene suture for scleral fixation without conjunctival dissection and to evaluate safety and efficacy outcomes associated with this technique.
Study: NCT03728244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEBO ointment
Description: The pharmacological effects of MEBO are attributable to beta-sitosterol, isolated from phellodendron amurense, flavonoids mainly baicalin isolated from scutellaria baicalensis, alkaloids mainly berberine, isolated from coptis chinensi, Beeswax and sesame oil (Zhang et al., 2005).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid gel
Description: Hyaluronic acid is a substance that is naturally present in the human body. It is found in the highest concentrations in fluids in the eyes and joints. The hyaluronic acid that is used as medicine is extracted from rooster combs or made by bacteria in the laboratory.
Study: NCT03119649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2222 50 mg
Description: Oral tablet(s) containing GLPG2222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2222 100 mg
Description: Oral tablet(s) containing GLPG2222

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral tablet(s) containing placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching oral tablet(s) containing placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching oral tablet(s) containing placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral tablet(s) containing placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching oral tablet(s) containing placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching oral tablet(s) containing placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2222 200 mg
Description: Oral tablet(s) containing GLPG2222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2222 400 mg
Description: Oral tablet(s) containing GLPG2222
Study: NCT04661696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel (albumin-bound)
Description: The dose of intravenous chemotherapy drug is calculated according to the body surface area.When patients have serious adverse events, dose suspension and dose reduction are allowed. Paclitaxel (albumin-bound) was allowed to be reduced only twice (20% standard dose reduction in the first dose and 20% lower in the second dose).Once the dose is reduced, all subsequent doses should be maintained at reduced dosage.
Study: NCT00663130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: Vardenafil 10mg, taken orally within 1 hour prior to sexual intercourse

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Tadalafil 10mg, taken orally within 1 hour prior to sexual intercourse
Study: NCT02739464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise + SOC PT/OT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SOC PT/OT
Study: NCT04375878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MS1819
Description: MS1819 in enteric capsules. It contains is a yeast-derived (non-porcine) lipase pancreatic enzyme replacement.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MS1819
Description: MS1819 in enteric capsules. It contains is a yeast-derived (non-porcine) lipase pancreatic enzyme replacement.
Study: NCT01267955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study: NCT02642042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03118557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates pelvic floor strengthening
Description: Pilates pelvic floor strengthening.
Study: NCT00706277

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol 2mg/kg for induction of anesthesia; followed by propofol 6 mg/kg/hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol 2mg
Study: NCT04375878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Porcine PERT
Description: Porcine PERT is being used a comparator to MS1819 as a second drug/intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Porcine PERT
Description: Porcine PERT is being used a comparator to MS1819 as a second drug/intervention.
Study: NCT00706277

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: remifentanil 0,25mcg/kg/hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: fentanyl 100mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane/Nitrous Oxide
Description: maintenance of anesthesia with sevoflurane and nitrous oxide
Study: NCT05260697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sexual counselling with plissit model
Description: sexual counselling
Study: NCT00152451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seletracetam (ucb 44212)
Description: * Pharmaceutical form: oral capsules~* Concentration: 10 and 50 mg~* Route of administration: oral administration
Study: NCT03904329

Intervention type: DRUG
Intervention: Oral Anticoagulant
Description: Oral tablets of anti coagulations either warfare or NOACs
Study: NCT00463684

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine
Description: Manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China; batch 200611A078-1. Administered subcutaneously in the right brachium.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated measles vaccine
Description: Manufactured by Serum Institute of India, Ltd, Pune, India; batch EU3244. Administered subcutaneously in the left brachium.
Study: NCT04501003

Intervention type: DEVICE
Group type: OTHER
Intervention: Bipolar cutting electrode (26040 BL1 Karl Storz, Tuttlingen)
Description: With the bipolar cutting electrode (26040 BL1 Karl Storz, Tuttlingen. Germany), a single incision was made from the bottom of the ostium onto the lateral walls up to the isthmus, with both lateral horns perpendicular to myometrium. The depth of the incision was between 5 and 7 mm. The cavity was widened to be triangular and symmetrical. Both tubal ostium surgeries were clearly observed at the end of the surgery. All patients were discharged on the day of surgery and no hormonal therapy and intrauterine balloon was applied after surgery. Approximately 3 months after the hysteroscopic T-shaped operation, an office hysteroscopy operation was planned to control patients in the secretory phase, to perform uterine cavity and post-operative fly control and to receive post-operative control endometrial biopsy specimens.
Study: NCT00115063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group sessions
Description: group sessions lead by a trained primary care clinic employee

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sibutramine, orlistat, diethylpropion
Description: dosage modified according to package insert instructions at discretion of primary care physicians

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Calorie Diet, Health One
Description: liquid diet for 8-12 weeks to induce weight loss

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Medical Combination Therapy for Obesity
Description: Very Low Calorie Liquid diet, Group Behavioral Therapy, Meal Replacement Therapy, Obesity Pharmacotherapy and a Treatment Toolbox.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Condition
Description: Access to the Mayo Clinic weight management website and usual care from the primary care physician
Study: NCT02477787

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic, donor-derived NK cells
Description: Patients in the study arm will receive donor NK cell infusion around days 13 and 20. A permissible range of infusion time will be +/- 3 days.~For DNKI to be given on day 13 (DNKI-1), the cell dose is 1-2 x108/kg or about the half of amount generated. For DNKI to be given on day 20 (DNKI-2), the cell dose is up to 5x108/kg.~Avil 1 ampoule will be given intravenously 30 minutes prior to each NK cell infusions.
Study: NCT02137330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Swallowable Obalon® Gastric Balloon
Study: NCT00966485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 80 mg ASA dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 500 mg ASA dosing
Study: NCT01717339

Intervention type: OTHER
Group type: OTHER
Intervention: Sleep Study

Intervention type: OTHER
Group type: OTHER
Intervention: Sleep Study
Study: NCT03733444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1690
Description: GLPG1690, film-coated tablets for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1690
Description: GLPG1690, film-coated tablets for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo, film-coated tablets for oral use.
Study: NCT05462327

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Fresh Gas Flow in Prone Position
Description: In the low fresh gas flow group, the flow rate was reduced to 0.5 L/min

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal Fresh Gas Flow in Prone Position
Description: In the normal flow rate group, the gas flow rate was reduced to 2 L/min during the maintenance phase.
Study: NCT01019421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AE58054
Description: Add-on treatment to donepezil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Add-on treatment to donepezil
Study: NCT01015625

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: lumpectomy or mastectomy with or without radiotherapy. Sentinel biopsy followed by axillary dissection (level I-II)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery on Demand
Description: if necessary local therapy on demand